Raj Vuppalanchi, MD
Professor of Medicine
Bio
Dr. Raj Vuppalanchi is a Professor of Medicine at Indiana University School of Medicine. He joined the division in 2007 after completing dual fellowships in Clinical Pharmacology and Gastroenterology/Hepatology from Indiana University School of Medicine. His clinical and research interests are in the areas of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), cholestatic and autoimmune liver disease (PSC, PBC, and AIH), biomarkers of fibrosis (transient elastography), and novel therapeutics for various liver disorders. He has expertise in hepatic safety of drugs and herbal and dietary supplements. He serves as a clinical investigator for industry and NIH-sponsored (NASH CRN and DILIN) multi-center clinical trials. He serves as the primary investigator for the Indiana CTSI Phase I clinical trials in the hepatic-impaired patient population.
Titles & Appointments
- Professor of Medicine
- Director of Hepatology
- Associate Program Director
-
Education2007 FEL Fellowship (Gastroenterology and Hepatology), IU School of Medicine, Indianapolis, IN2005 FEL Fellowship (Clinical Pharmacology), IU School of Medicine, Indianapolis, IN2003 RES Residency, Long Island College Hospital, Brooklyn, NY1998 MB,BS Gandhi Medical College
-
Research
His research interests include pathogenesis and therapy for nonalcoholic steatohepatitis (NASH) and drug induced liver injury (DILI). His other research interests include studying alterations in drug metabolism in patients who underwent gastric bypass and patients who have cirrhosis. He is currently working on understanding the pathogenesis and treatment of muscle cramps in patients with cirrhosis.
-
PublicationsAn Outbreak Presents An Opportunity to Learn About A Rare Phenotype: Autoimmune Hepatitis After Acute Hepatitis A.
S-Are V; Yoder L; Samala N; Nephew L; Lammert C; Vuppalanchi R; Annals of hepatology 2020 Sep 12Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; STELLAR-3 and STELLAR-4 Investigators.; Journal of hepatology 2020 Mar 6A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL; AESOP Study Investigators.; Journal of hepatology 2020 Mar 10Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Vilar-Gomez E; Vuppalanchi R; Desai A; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N; Alimentary pharmacology & therapeutics 2019 Jun 3Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography?
Vuppalanchi R; Weber R; Russell S; Gawrieh S; Samala N; Slaven JE; Harden L; Chalasani N; The American journal of gastroenterology 2019 JunOlder Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis.
Dakhoul L; Jones KR; Gawrieh S; Ghabril M; McShane C; Vuppalanchi R; Vilar-Gomez E; Nephew L; Chalasani N; Lammert C; Digestive diseases and sciences 2019 Jan 7Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ; NASH Clinical Research Network.; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019 Jan 4Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters.
Zemel MB; Kolterman O; Rinella M; Vuppalanchi R; Flores O; Barritt AS 4th; Siddiqui M; Chalasani N; Obesity (Silver Spring, Md.) 2019 JanA Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.
Mayo MJ; Pockros PJ; Jones D; Bowlus CL; Levy C; Patanwala I; Bacon B; Luketic V; Vuppalanchi R; Medendorp S; Dorenbaum A; Kennedy C; Novak P; Gu J; Apostol G; Hirschfield GM; Hepatology communications 2019 Feb 1HEP-18-0797.R2 - Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
Vuppalanchi R; Chalasani N; Hepatology (Baltimore, Md.) 2019 Apr 5Ischemic Cholangiopathy 11 Years after Liver Transplantation from Asymptomatic Chronic Hepatic Artery Thrombosis.
Krajicek E; Sherman S; Lacerda M; Johnson MS; Vuppalanchi R; ACG case reports journal 2018 Oct 24Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E; Alimentary pharmacology & therapeutics 2018 Nov 14Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details.
Vuppalanchi R; Mathur K; Pyko M; Samala N; Chalasani N; Hepatology (Baltimore, Md.) 2018 Nov 12Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.
Vilar-Gomez E; Vuppalanchi R; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N; Hepatology (Baltimore, Md.) 2018 Dec 1Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.
Cheng YW; Phelps E; Ganapini V; Khan N; Ouyang F; Xu H; Khanna S; Tariq R; Friedman-Moraco RJ; Woodworth MH; Dhere T; Kraft CS; Kao D; Smith J; Le L; El-Nachef N; Kaur N; Kowsika S; Ehrlich A; Smith M; Safdar N; Misch EA; Allegretti JR; Flynn A; Kassam Z; Sharfuddin A; Vuppalanchi R; Fischer M; American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018 Aug 31When Enough Is Not Enough: Screening, Brief Intervention and Referral to Treatment for Hepatitis C in Patients Presenting to the Emergency Department.
Yoder L; Vuppalanchi R; Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2018 Aug 24Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ; NASH Clinical Research Network.; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018 Apr 26Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease.
Chalasani N; Vuppalanchi R; Rinella M; Middleton MS; Siddiqui MS; Barritt AS 4th; Kolterman O; Flores O; Alonso C; Iruarrizaga-Lejarreta M; Gil-Redondo R; Sirlin CB; Zemel MB; Alimentary pharmacology & therapeutics 2018 Apr 25Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease.
Yates KP; Deppe R; Comerford M; Masuoka H; Cummings OW; Tonascia J; Chalasani N; Vuppalanchi R; NASH CRN.; PloS one 2017 Nov 2Most Individuals With Advanced Cirrhosis Have Sleep Disturbances, Which Are Associated With Poor Quality of Life.
Ghabril M; Jackson M; Gotur R; Weber R; Orman E; Vuppalanchi R; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017 Feb 3Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration.
Mukthinuthalapati PK; Fontana RJ; Vuppalanchi R; Chalasani N; Ghabril M; Journal of clinical gastroenterology 2017 Aug 8Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.
Vuppalanchi R; Siddiqui MS; Van Natta ML; Hallinan E; Brandman D; Kowdley K; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Abdelmalek M; Doo E; Tonascia JA; Kleiner DE; Sanyal AJ; Chalasani N; NASH Clinical Research Network.; Hepatology (Baltimore, Md.) 2017 Aug 31Secondary Sclerosing Cholangitis From Spontaneous Choledochoduodenal Fistula.
Gromski MA; Fogel EL; Vuppalanchi R; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Sep 23Differential Expression of miRNAs in Nontumor Liver Tissue of Patients With Hepatocellular Cancer Caused by Nonalcoholic Steatohepatitis Cirrhosis.
Liang T; Chalasani NP; Williams KE; Sarasani V; Janga SC; Vuppalanchi R; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Oct 22Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
Eadon MT; Desta Z; Levy KD; Decker BS; Pierson RC; Pratt VM; Callaghan JT; Rosenman MB; Carpenter JS; Holmes AM; McDonald CA; Benson EA; Patil AS; Vuppalanchi R; Gufford BT; Dave N; Robarge JD; Hyder MA; Haas DM; Kreutz RP; Dexter PR; Skaar TC; Flockhart DA; Clinical pharmacology and therapeutics 2016 Mar 31Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat.
Vuppalanchi R; Chalasani N; Digestive diseases and sciences 2016 JulFebuxostat-induced acute liver injury.
Bohm M; Vuppalanchi R; Chalasani N; Drug-Induced Liver Injury Network (DILIN).; Hepatology (Baltimore, Md.) 2016 Feb 3Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.
Vuppalanchi R; Saxena R; Storniolo AMV; Chalasani N; Hepatology (Baltimore, Md.) 2016 Aug 9Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study.
Zheng EX; Rossi S; Fontana RJ; Vuppalanchi R; Hoofnagle JH; Khan I; Navarro VJ; Drug safety 2016 AugSteatosis and liver stiffness measurements using transient elastography.
Eddowes P; Sasso M; Fournier C; Vuppalanchi R; Newsome P; Hepatology (Baltimore, Md.) 2016 Apr 4Endoscopic Sedation in Roux-en-Y Gastric Bypass.
Vuppalanchi R; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 Sep 16Reply: To PMID 24395623.
Martinez M; Tandra A; Vuppalanchi R; Hepatology (Baltimore, Md.) 2015 Mar 9Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate.
Fischer M; Sipe BW; Rogers NA; Cook GK; Robb BW; Vuppalanchi R; Rex DK; Alimentary pharmacology & therapeutics 2015 Jun 19Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis.
Masuoka HC; Vuppalanchi R; Deppe R; Bybee P; Comerford M; Liangpunsakul S; Ghabril M; Chalasani N; Digestive diseases and sciences 2015 Jul 21Erratum to: Severe Drug-Induced Skin and Liver Injury from Rivaroxaban.
Barrett P; Vuppalanchi R; Masuoka H; Chalasani N; Digestive diseases and sciences 2015 JulHerbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research.
Vuppalanchi R; Navarro V; Vega M; Bonkovsky HL; Seeff L; Serrano J; Drug-Induced Liver Injury Network (DILIN).; Gastroenterology 2015 Jan 8Severe drug-induced skin and liver injury from rivaroxaban.
Barrett P; Vuppalanchi R; Masuoka H; Chalasani N; Digestive diseases and sciences 2015 Jan 6A not-so-sweet diagnosis: secondary biliary cirrhosis from a "lollipop" stone.
Gromski MA; Vuppalanchi R; Sherman S; Fogel EL; Gastrointestinal endoscopy 2015 Dec 18Reply: To PMID 24395623.
Martinez M; Tandra A; Vuppalanchi R; Hepatology (Baltimore, Md.) 2015 Apr 18Myths and mysteries about staging hepatic fibrosis by fibroscan.
Vuppalanchi R; Sanyal AJ; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2014 Nov 5Drug-induced nodular regenerative hyperplasia.
Ghabril M; Vuppalanchi R; Seminars in liver disease 2014 May 31Treatment of acute portal vein thrombosis by nontraditional anticoagulation.
Martinez M; Tandra A; Vuppalanchi R; Hepatology (Baltimore, Md.) 2014 May 27Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease.
Vuppalanchi R; Jain AK; Deppe R; Yates K; Comerford M; Masuoka HC; Neuschwander-Tetri BA; Loomba R; Brunt EM; Kleiner DE; Molleston JP; Schwimmer JB; Lavine JE; Tonascia J; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2014 May 17HIV-1 coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects.
Hu S; Ghabril M; Amet T; Hu N; Byrd D; Yang K; Vuppalanchi R; Saxena R; Desai M; Lan J; Johnson R; Gupta S; Chalasani N; Yu Q; PloS one 2014 Feb 6Magic wand and crystal ball for primary sclerosing cholangitis.
Vuppalanchi R; Lindor K; Gastroenterology 2014 Feb 22Clinical and histologic features of azithromycin-induced liver injury.
Martinez MA; Vuppalanchi R; Fontana RJ; Stolz A; Kleiner DE; Hayashi PH; Gu J; Hoofnagle JH; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2014 Aug 9Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
Force J; Saxena R; Schneider BP; Storniolo AM; Sledge GW Jr; Chalasani N; Vuppalanchi R; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 28Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis.
Vuppalanchi R; Liang T; Goswami CP; Nalamasu R; Li L; Jones D; Wei R; Liu W; Sarasani V; Janga SC; Chalasani N; PloS one 2013 Sep 13De novo malignancy post-liver transplantation: a single center, population controlled study.
Chatrath H; Berman K; Vuppalanchi R; Slaven J; Kwo P; Tector AJ; Chalasani N; Ghabril M; Clinical transplantation 2013 Jun 30Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.
Vuppalanchi R; Gotur R; Reddy KR; Fontana RJ; Ghabril M; Kosinski AS; Gu J; Serrano J; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013 Dec 20Serum hepcidin levels are associated with obesity but not liver disease.
Vuppalanchi R; Troutt JS; Konrad RJ; Ghabril M; Saxena R; Bell LN; Kowdley KV; Chalasani N; Obesity (Silver Spring, Md.) 2013 Dec 17Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
Tandra S; Chalasani N; Jones DR; Mattar S; Hall SD; Vuppalanchi R; Annals of surgery 2013 AugDyslipidemia in patients with nonalcoholic fatty liver disease.
Chatrath H; Vuppalanchi R; Chalasani N; Seminars in liver disease 2012 Mar 13Serum proteomic profiling in patients with drug-induced liver injury.
Bell LN; Vuppalanchi R; Watkins PB; Bonkovsky HL; Serrano J; Fontana RJ; Wang M; Rochon J; Chalasani N; US Drug-Induced Liver Injury Network (DILIN) Research Group.; Alimentary pharmacology & therapeutics 2012 MarAcute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series.
Chalasani N; Vuppalanchi R; Navarro V; Fontana R; Bonkovsky H; Barnhart H; Kleiner DE; Hoofnagle JH; Annals of internal medicine 2012 Jun 19Prevalence and morbidity associated with muscle cramps in patients with cirrhosis.
Chatrath H; Liangpunsakul S; Ghabril M; Otte J; Chalasani N; Vuppalanchi R; The American journal of medicine 2012 Jul 24Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
Quinney SK; Malireddy SR; Vuppalanchi R; Hamman MA; Chalasani N; Gorski JC; Hall SD; European journal of clinical pharmacology 2012 Jul 10The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings.
Vuppalanchi R; Kwo PY; Gastroenterology 2012 Dec 20Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements.
Vuppalanchi R; Juluri R; Bell LN; Ghabril M; Kamendulis L; Klaunig JE; Saxena R; Agarwal D; Johnson MS; Chalasani N; The American journal of the medical sciences 2011 OctHepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.
Bell LN; Molleston JP; Morton MJ; Klipsch A; Saxena R; Vuppalanchi R; Chalasani N; Journal of clinical gastroenterology 2011 OctClinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.
Vuppalanchi R; Gould RJ; Wilson LA; Unalp-Arida A; Cummings OW; Chalasani N; Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).; Hepatology international 2011 May 10Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease.
Juluri R; Vuppalanchi R; Olson J; Unalp A; Van Natta ML; Cummings OW; Tonascia J; Chalasani N; Journal of clinical gastroenterology 2011 JanDrug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Vuppalanchi R; Juluri R; Ghabril M; Kim S; Thong N; Gorski JC; Chalasani N; Hall SD; Journal of clinical gastroenterology 2011 AugDuloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.
Vuppalanchi R; Hayashi PH; Chalasani N; Fontana RJ; Bonkovsky H; Saxena R; Kleiner D; Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN).; Alimentary pharmacology & therapeutics 2010 Sep 3The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.
Misra VL; Vuppalanchi R; Jones D; Hamman M; Kwo PY; Kahi C; Chalasani N; Alimentary pharmacology & therapeutics 2010 OctIncidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.
Berman K; Tandra S; Forssell K; Vuppalanchi R; Burton JR Jr; Nguyen J; Mullis D; Kwo P; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010 Nov 17Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.
Bell LN; Temm CJ; Saxena R; Vuppalanchi R; Schauer P; Rabinovitz M; Krasinskas A; Chalasani N; Mattar SG; Annals of surgery 2010 JunSerum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease.
Bell LN; Theodorakis JL; Vuppalanchi R; Saxena R; Bemis KG; Wang M; Chalasani N; Hepatology (Baltimore, Md.) 2010 JanSerum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine.
Bell LN; Lee L; Saxena R; Bemis KG; Wang M; Theodorakis JL; Vuppalanchi R; Alloosh M; Sturek M; Chalasani N; American journal of physiology. Gastrointestinal and liver physiology 2010 Feb 18Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study.
Berman K; Tandra S; Vuppalanchi R; Ghabril M; Sandrasegaran K; Nguyen J; Caffrey H; Liangpunsakul S; Lumeng L; Kwo P; Chalasani N; The American journal of gastroenterology 2010 Dec 21Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.
Tandra S; Yeh MM; Brunt EM; Vuppalanchi R; Cummings OW; Ünalp-Arida A; Wilson LA; Chalasani N; Journal of hepatology 2010 Dec 21Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Vuppalanchi R; Chalasani N; Hepatology (Baltimore, Md.) 2009 JanUse of statins in patients with liver disease.
Tandra S; Vuppalanchi R; Current treatment options in cardiovascular medicine 2009 AugEffects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.
Vuppalanchi R; Unalp A; Van Natta ML; Cummings OW; Sandrasegaran KE; Hameed T; Tonascia J; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008 Dec 25Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.
Kolwankar D; Vuppalanchi R; Ethell B; Jones DR; Wrighton SA; Hall SD; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2007 MarEtiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?
Vuppalanchi R; Liangpunsakul S; Chalasani N; The American journal of gastroenterology 2007 MarRelationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples.
Vuppalanchi R; Cummings OW; Saxena R; Ulbright TM; Martis N; Jones DR; Bansal N; Chalasani N; Journal of clinical gastroenterology 2007 FebIsolated melanosis of the gastric antrum: an unusual endoscopic finding.
Vuppalanchi R; Vakili ST; Kahi CJ; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006 Dec 4Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide.
Vuppalanchi R; Chalasani N; Saxena R; The American journal of surgical pathology 2006 DecGlycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study.
Chalasani N; Vuppalanchi R; Raikwar NS; Deeg MA; The Journal of clinical endocrinology and metabolism 2006 Apr 4Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.
Vuppalanchi R; Marri S; Kolwankar D; Considine RV; Chalasani N; Journal of clinical gastroenterology 2005 MarPatients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
Vuppalanchi R; Teal E; Chalasani N; The American journal of the medical sciences 2005 Feb -
Professional OrganizationsAmerican Association for Study of Liver DiseasesAmerican College of Gastroenterology
-
Board CertificationsAmerican Board of Internal Medicine - Internal MedicineAmerican Board of Internal Medicine - Gastroenterology
-
Clinical Interests
Dr. Vuppalanchi's clinical interests include management of cirrhosis, non-alcoholic fatty liver, chronic hepatitis C and B, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease and drug induced liver injury.
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.